Umbelliprenin treatment significantly downregulated the mRNA of Oct4, Nanog, and SOX2, suggesting umbelliprenin as a putative pancreatic cancer stem cell killing drug. The gene discussed is SOX2; the disease is pancreatic neoplasm.